Hilleman Laboratories

Hilleman Laboratories is a research organisation jointly established by MSD and the Wellcome Trust to develop affordable and accessible vaccines and biologics that meet public health needs in low- and middle-income countries. It occupies a unique niche in the vaccine development process by focusing on early-stage development of vaccines and biologics up to Phase 2 clinical trials, to bridge the gap to commercial viability.

Hilleman set up its regional base in Singapore in 2021. The decision to move its headquarters from India was made in recognition of Singapore’s thriving biomedical sciences sector and robust intellectual property (IP) framework. As a translational research organisation, Hilleman’s mainstay is developing novel platforms and products to improve global health. Strong IP protection is thus vital for it to safeguard its inventions, even as it continues to forge partnerships within the local biomedical ecosystem and expands its footprint globally.

"Singapore’s intellectual property framework enables us to carry out R&D activities with the assurance that our inventions are well protected. Being able to plug in to the local biomedical ecosystem has also enabled us to collaborate with Singapore-based institutions and agencies on innovation projects and initiatives that could have significant local and global public health impact."

- Mr Ali Alloueche, Vice President and Global Head for Business Development, Alliance Management & External R&D

Hilleman currently has eight patent families covering vaccine products for cholera, meningitis and rotavirus, as well as technology platforms used for the production and manufacturing of these vaccines. This portfolio is expected to expand significantly over the next 3-5 years as a result of Hilleman’s focus on viral recombinant and RNA vaccines.

Find out more at Hilleman Laboratories: Overview | LinkedIn